Literature DB >> 15477536

Hyperinsulinemia and risk of Alzheimer disease.

Jose A Luchsinger1, Ming-Xin Tang, Steven Shea, Richard Mayeux.   

Abstract

OBJECTIVE: To explore the association between fasting insulin levels and dementia.
METHODS: Fasting insulin levels were measured from frozen sera using solid-phase chemiluminescent enzyme immunoassay in a sample of elderly subjects chosen at random from a cohort of persons aged 65 years and older from northern Manhattan. Dementia was diagnosed using standard methods. Neuropsychiatric testing was available on all subjects at each follow-up interval.
RESULTS: A total of 683 subjects without prevalent dementia were followed for 3,691 person-years and 149 persons developed dementia (137 Alzheimer disease [AD], 6 dementia associated with stroke, 6 other). The risk of AD doubled in the 39% of the sample with hyperinsulinemia (HR = 2.1; 95% CI: 1.5, 2.9) and was highest in people without diabetes. The HR relating presence of hyperinsulinemia or diabetes in 50% of our sample to AD was 2.2 (95% CI: 1.5, 3.1). The risk of AD attributable to the presence of hyperinsulinemia or diabetes was 39%. The HR of AD for the highest quartile of insulin compared to the lowest was 1.7 (95% CI: 1.0, 2.7; p for trend = 0.009). Hyperinsulinemia was also related to a significant decline in memory-related cognitive scores, but not to decline in other cognitive domains.
CONCLUSIONS: Hyperinsulinemia is associated with a higher risk of AD and decline in memory.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15477536     DOI: 10.1212/01.wnl.0000140292.04932.87

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  222 in total

1.  Polyadenylation of nascent RNA during the embryogenesis of Ilyanassa obsoleta.

Authors:  J R Collier
Journal:  Exp Cell Res       Date:  1975-10-15       Impact factor: 3.905

2.  Insulin receptor β-subunit haploinsufficiency impairs hippocampal late-phase LTP and recognition memory.

Authors:  Robert Nisticò; Virve Cavallucci; Sonia Piccinin; Simone Macrì; Marco Pignatelli; Bisan Mehdawy; Fabio Blandini; Giovanni Laviola; Davide Lauro; Nicola B Mercuri; Marcello D'Amelio
Journal:  Neuromolecular Med       Date:  2012-06-03       Impact factor: 3.843

Review 3.  Patterns of compensation and vulnerability in normal subjects at risk of Alzheimer's disease.

Authors:  Oscar L Lopez; James T Becker; Lewis H Kuller
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

Review 4.  Role of insulin resistance in Alzheimer's disease.

Authors:  Zhiyou Cai; Ming Xiao; Liying Chang; Liang-Jun Yan
Journal:  Metab Brain Dis       Date:  2014-11-16       Impact factor: 3.584

5.  Cerebrovascular lesions induce transient β-amyloid deposition.

Authors:  Monica Garcia-Alloza; Julia Gregory; Kishore V Kuchibhotla; Sara Fine; Ying Wei; Cenk Ayata; Matthew P Frosch; Steven M Greenberg; Brian J Bacskai
Journal:  Brain       Date:  2011-11-26       Impact factor: 13.501

Review 6.  Diet and Alzheimer's disease.

Authors:  José A Luchsinger; James M Noble; Nikolaos Scarmeas
Journal:  Curr Neurol Neurosci Rep       Date:  2007-09       Impact factor: 5.081

7.  Metabolic syndrome and cognitive decline in early Alzheimer's disease and healthy older adults.

Authors:  Amber S Watts; Natalia Loskutova; Jeffrey M Burns; David K Johnson
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

8.  Cognitive decline and cardiometabolic risk among Hispanic and non-Hispanic white adults in the San Luis Valley Health and Aging Study.

Authors:  Kerry L Hildreth; Jim Grigsby; Lucinda L Bryant; Pamela Wolfe; Judith Baxter
Journal:  J Behav Med       Date:  2013-01-18

Review 9.  Alzheimer's disease and type 2 diabetes: multiple mechanisms contribute to interactions.

Authors:  Anusha Jayaraman; Christian J Pike
Journal:  Curr Diab Rep       Date:  2014-04       Impact factor: 4.810

Review 10.  Intranasal insulin therapy for cognitive impairment and neurodegeneration: current state of the art.

Authors:  Suzanne M de la Monte
Journal:  Expert Opin Drug Deliv       Date:  2013-11-12       Impact factor: 6.648

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.